|
CONNECT Trial Strengthens the Case for CGM in Non-Insulin Type 2 Diabetes
|
Written by: J. Smith |
Hits: 148
|
|
Dexcom G8 Promises Smaller Size and Adaptive Accuracy
|
Written by: J. Smith |
Hits: 278
|
|
New ACHIEVE-4 Data May Help Address FDA Safety Questions on Lilly’s Foundayo
|
Written by: J. Smith |
Hits: 214
|
|
Novo Nordisk Expands AI Strategy Through New OpenAI Partnership
|
Written by: J. Smith |
Hits: 266
|
|
Lilly’s Foundayo Approval Brings a More Flexible GLP-1 Pill to Weight Loss Care
|
Written by: J. Smith |
Hits: 223
|
|
Novo Nordisk Reports Promising Phase 2 Data for UBT251 in Type 2 Diabetes
|
Written by: J. Smith |
Hits: 211
|
|
Novo Nordisk Expands DTC Push With New Wegovy Subscription Program
|
Written by: J. Smith |
Hits: 215
|
|
FDA Approves Awiqli as First Once-Weekly Basal Insulin for Type 2 Diabetes
|
Written by: J. Smith |
Hits: 226
|
|
Retatrutide’s First Phase 3 Diabetes Results Draw Attention for More Than Strong Numbers
|
Written by: J. Smith |
Hits: 448
|
|
FDA Approves Wegovy HD, Adding a Higher-Dose Semaglutide Option for Obesity
|
Written by: J. Smith |
Hits: 261
|
